The global sepsis diagnostics market size was estimated to be USD 734.62 million in 2023 and is expected to reach at USD 2,062.7 million by 2033 with a CAGR of 9.84% during the forecast period 2023-2033. Growing prevalence of sepsis, rising awareness regarding the disease, surge in research & development activities, increasing demand for rapid diagnostic tests, growing regulatory approval, rising technologically advanced diagnostic solutions, surge in prevalence of Hospital-Acquired Infections (HAIs), and rising introduction of technologically advanced diagnostic solutions are some of the key factors boosting the market growth.
Rising introduction of technologically advanced diagnostic solutions is predicted to boost the market growth during the forecast period. For instance, in May 2020, The newest DxH 690T hematology analyzer from Beckman Coulter has been launched in the United States and has early sepsis signs.
By Product, Blood culture media was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to increasing prevalence of sepsis cases, growing geriatric population, rising incidence of bloodstream infection, surge in demand for rapid diagnostic techniques, and growing product approvals by regulatory bodies. For instance, in May 2022, Health Canada has granted approval to bioMerieux SA for the BIOFIRE Blood Culture Identification 2 (BCID2) Panel, a rapid molecular diagnostic tool used to detect bloodstream infections. Additionally, Instruments is predicted to grow at fastest CAGR during the forecast period owing to the growing awareness regarding healthcare among the population, rising number of surgical procedures, and increasing technological advancements.
By Technology, Microbiology was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to the use of culture medium tests in combination with microbiological technologies to accurately detect & identify bacteria for sepsis diagnosis and growing strategic initiatives such as mergers & acquisitions by key market players. For instance, in April 2022, bioMerieux SA has successfully acquired Specific Diagnostics, a company that has created the SPECIFIC REVEAL rapid AST (antimicrobial susceptibility test) system. Additionally, Molecular diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of molecular diagnostic technology due to its several advantages, such as high sensitivity, accuracy, and less turnaround time, over other technologies.
By Method, Automated diagnostic was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to the growing research & development activities by market players and increasing launch of advanced products. For instance, in December 2020, According to an article in SelectScience, Molzym GmbH & Co. KG, in collaboration with Fraunhofer IZI-BB research institute, has introduced an automated test named AutoSepT, which allows rapid pathogen detection directly from samples in under five hours. Additionally, Conventional diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the traditional approach of diagnosing sepsis depends on the knowledge of healthcare professionals to assess the patient's clinical presentation and interpret lab & imaging data, increasing demand for early detection & prompt treatment of sepsis.
By Pathogen, Bacterial sepsis was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to the increasing prevalence of bacterial sepsis, surge in occurrence of hospital-acquired infections, and rising number of surgical procedures conducted. Additionally, Fungal sepsis is predicted to grow at fastest CAGR during the forecast period owing to the rising research & development activities, surge in introduction of new devices, and growing regulatory approvals of novel products. For instance, in January 2021, Bruker has obtained clearance from the U.S. FDA and introduced the MBT Sepsityper Kit U.S. IVD, which enables rapid microbial identification of over 425 microorganisms found in positive blood cultures on the MALDI Biotyper CA System.
By Testing, Laboratory testing was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to the fact that POC testing is less accurate than lab testing when diagnosing sepsis, growing demand for in-depth analysis of the pathogen & its drug resistance profile, surge in launch of technologically advanced products, increasing reliance of the public & physicians on these labs, and rising number of diagnostic laboratories. Additionally, PoC testing is predicted to grow at fastest CAGR during the forecast period owing to the rising technological advancements and surge in launch of advanced product such as rapid diagnostics & PoC techniques. For instance, in June 2021, Cytovale, Inc. has revealed that recently presented data on its IntelliSep® test provide additional evidence of its capacity to assist in swift and clinically significant sepsis diagnoses in emergency departments (EDs).
By End-user, Hospital & clinics was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to the increase in hospitalization, rising developments in advance diagnostic tests, surge in product approvals by regulatory bodies, and growing partnerships within market players. For instance, in January 2022, Siemens Healthcare GmbH has formed a partnership with American Hospital Dubai to offer advanced solutions for diagnostic imaging and lab diagnostics equipment. Additionally, Pathology & reference laboratories is predicted to grow at fastest CAGR during the forecast period owing to the rising healthcare infrastructure in pathology & reference laboratories and growing technological advancements.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing adoption of advanced diagnostic solutions, rising presence of key market players, increasing reimbursement policies, surge in well-established healthcare infrastructure, growing incidence of sepsis & infectious diseases, and rising collaborations within market players. For instance, in August 2022, BD and Accelerate Diagnostics have joined forces to present a complete solution for sepsis management. Through this collaboration, healthcare providers will have access to quicker and more precise diagnostic tools, showcasing their mutual dedication to enhancing the field of sepsis management and enhancing patient outcomes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for sepsis diagnostic solutions, growing prevalence of infectious diseases, rising initiatives by market players, surge in technological advancements, and increasing initiatives by market players. For instance, in February 2022, T2 Biosystems, Inc. has revealed the signing of exclusive distribution agreements in Norway, Finland, and Türkiye. These agreements will enable the sale of T2Dx® Instruments, along with T2Bacteria®, T2Candida®, and T2Resistance® Panels through the appointed distributors in those territories.
Rising introduction of technologically advanced diagnostic solutions is predicted to boost the market growth during the forecast period. For instance, in May 2020, The newest DxH 690T hematology analyzer from Beckman Coulter has been launched in the United States and has early sepsis signs.
By Product, Blood culture media was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to increasing prevalence of sepsis cases, growing geriatric population, rising incidence of bloodstream infection, surge in demand for rapid diagnostic techniques, and growing product approvals by regulatory bodies. For instance, in May 2022, Health Canada has granted approval to bioMerieux SA for the BIOFIRE Blood Culture Identification 2 (BCID2) Panel, a rapid molecular diagnostic tool used to detect bloodstream infections. Additionally, Instruments is predicted to grow at fastest CAGR during the forecast period owing to the growing awareness regarding healthcare among the population, rising number of surgical procedures, and increasing technological advancements.
By Technology, Microbiology was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to the use of culture medium tests in combination with microbiological technologies to accurately detect & identify bacteria for sepsis diagnosis and growing strategic initiatives such as mergers & acquisitions by key market players. For instance, in April 2022, bioMerieux SA has successfully acquired Specific Diagnostics, a company that has created the SPECIFIC REVEAL rapid AST (antimicrobial susceptibility test) system. Additionally, Molecular diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of molecular diagnostic technology due to its several advantages, such as high sensitivity, accuracy, and less turnaround time, over other technologies.
By Method, Automated diagnostic was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to the growing research & development activities by market players and increasing launch of advanced products. For instance, in December 2020, According to an article in SelectScience, Molzym GmbH & Co. KG, in collaboration with Fraunhofer IZI-BB research institute, has introduced an automated test named AutoSepT, which allows rapid pathogen detection directly from samples in under five hours. Additionally, Conventional diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the traditional approach of diagnosing sepsis depends on the knowledge of healthcare professionals to assess the patient's clinical presentation and interpret lab & imaging data, increasing demand for early detection & prompt treatment of sepsis.
By Pathogen, Bacterial sepsis was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to the increasing prevalence of bacterial sepsis, surge in occurrence of hospital-acquired infections, and rising number of surgical procedures conducted. Additionally, Fungal sepsis is predicted to grow at fastest CAGR during the forecast period owing to the rising research & development activities, surge in introduction of new devices, and growing regulatory approvals of novel products. For instance, in January 2021, Bruker has obtained clearance from the U.S. FDA and introduced the MBT Sepsityper Kit U.S. IVD, which enables rapid microbial identification of over 425 microorganisms found in positive blood cultures on the MALDI Biotyper CA System.
By Testing, Laboratory testing was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to the fact that POC testing is less accurate than lab testing when diagnosing sepsis, growing demand for in-depth analysis of the pathogen & its drug resistance profile, surge in launch of technologically advanced products, increasing reliance of the public & physicians on these labs, and rising number of diagnostic laboratories. Additionally, PoC testing is predicted to grow at fastest CAGR during the forecast period owing to the rising technological advancements and surge in launch of advanced product such as rapid diagnostics & PoC techniques. For instance, in June 2021, Cytovale, Inc. has revealed that recently presented data on its IntelliSep® test provide additional evidence of its capacity to assist in swift and clinically significant sepsis diagnoses in emergency departments (EDs).
By End-user, Hospital & clinics was the highest revenue-grossing segment in the global sepsis diagnostics market in 2022 owing to the increase in hospitalization, rising developments in advance diagnostic tests, surge in product approvals by regulatory bodies, and growing partnerships within market players. For instance, in January 2022, Siemens Healthcare GmbH has formed a partnership with American Hospital Dubai to offer advanced solutions for diagnostic imaging and lab diagnostics equipment. Additionally, Pathology & reference laboratories is predicted to grow at fastest CAGR during the forecast period owing to the rising healthcare infrastructure in pathology & reference laboratories and growing technological advancements.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing adoption of advanced diagnostic solutions, rising presence of key market players, increasing reimbursement policies, surge in well-established healthcare infrastructure, growing incidence of sepsis & infectious diseases, and rising collaborations within market players. For instance, in August 2022, BD and Accelerate Diagnostics have joined forces to present a complete solution for sepsis management. Through this collaboration, healthcare providers will have access to quicker and more precise diagnostic tools, showcasing their mutual dedication to enhancing the field of sepsis management and enhancing patient outcomes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for sepsis diagnostic solutions, growing prevalence of infectious diseases, rising initiatives by market players, surge in technological advancements, and increasing initiatives by market players. For instance, in February 2022, T2 Biosystems, Inc. has revealed the signing of exclusive distribution agreements in Norway, Finland, and Türkiye. These agreements will enable the sale of T2Dx® Instruments, along with T2Bacteria®, T2Candida®, and T2Resistance® Panels through the appointed distributors in those territories.
Segmentation: Sepsis Diagnostics Market Report 2022 - 2033
Sepsis Diagnostics Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Mn)
- Blood Culture Media
- Instruments
- Software
- Assay Kits and Reagents
Sepsis Diagnostics Market Analysis & Forecast by Technology 2022 - 2033 (Revenue USD Mn)
- Immunoassays
- Microbiology
- Flow Cytometry
Molecular Diagnostics
- DNA Microarrays
- Syndromic Panel testing
- Polymerase Chain Reaction (PCR)
- Others
- Others
Sepsis Diagnostics Market Analysis & Forecast by Method 2022 - 2033 (Revenue USD Mn)
- Automated Diagnostics
- Conventional Diagnostics
Sepsis Diagnostics Market Analysis & Forecast by Pathogen 2022 - 2033 (Revenue USD Mn)
- Viral Sepsis
- Fungal Sepsis
Bacterial Sepsis
- Gram-positive Bacteria
- Gram-negative Bacteria
- Others
Sepsis Diagnostics Market Analysis & Forecast by Testing 2022 - 2033 (Revenue USD Mn)
- PoC Testing
- Laboratory Testing
Sepsis Diagnostics Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Mn)
- Research Institutes
- Hospitals & Clinics
- Pathology & Reference Laboratories
- Others
Sepsis Diagnostics Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Mn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Sepsis Diagnostics Market: Product Estimates & Trend Analysis
8. Sepsis Diagnostics Market: Technology Estimates & Trend Analysis
9. Sepsis Diagnostics Market: Method Estimates & Trend Analysis
10. Sepsis Diagnostics Market: Pathogen Estimates & Trend Analysis
11. Sepsis Diagnostics Market: Testing Estimates & Trend Analysis
12. Sepsis Diagnostics Market: End-user Estimates & Trend Analysis
13. Regional Market Analysis
14. North America Sepsis Diagnostics Market
15. Europe Global Sepsis Diagnostics Market
16. Asia Pacific Global Sepsis Diagnostics Market
17. Latin America Global Sepsis Diagnostics Market
18. MEA Global Sepsis Diagnostics Market
19. Competitor Analysis
20. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche AG
- bioMérieux SA
- Koninklijke Philips N.V.
- Thermo Fisher Scientific Inc.
- Becton
- Dickinson and Company
- Luminex Corp.
- Bruker Corporation
- Immunexpress Inc.
- Cepheid
- Danaher Corporation (Beckman Coulter Inc.)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 734.62 Million |
| Forecasted Market Value ( USD | $ 2062.7 Million |
| Compound Annual Growth Rate | 9.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
